Evidence that AI-fueled drug discovery is the way forward is hard to find now, but that could change in 2025. After merging with Exscientia, Recursion will have 10 clinical readouts to look forward to ...

Recursion Pharmaceuticals (RXRX), a trailblazer in AI-powered drug discovery, recently acquired its competitor, Exscientia, in a strategic move that solidifies its leading position in the industry.

With a one-of-a-kind platform that can run and analyze millions of experiments at a time, Recursion could change the drug-discovery process. The stock market, though, isn't that impressed, and the ...

While there have been many sober warnings about AI and recursive self-improvement, Arianna Huffington argues that it is a ...

Chris Gibson, Recursion Pharmaceuticals CEO, joins 'Closing Bell Overtime' to talk its partnership with Nvidia, its investors day, drug discovery and more. Got a confidential news tip? We want to hear ...

Important messages require accurate transmission. Big genes are especially challenging. During processing, introns (non-coding elements) are snipped out and exons (coding segments) pasted together to ...

The word “recursion” is the latest buzzword in AI circles. Two separate startups have taken on the name, and many more have started referencing recursive self-improvement (RSI) in their roadmaps. Like ...

Brains sell magazines, mathematical linguistics sells caffeine. That basically summarizes coverage of a recent study on songbirds' "artificial grammar system". More on that later. First, a summary of ...

** This episode was originally published on June 20, 2019. It runs across cultures, through science, mathematics and art. It's as common as the branches on a tree or the layers of a Russian doll — but ...